BR112018015629A2 - "compound, composition, method for treating a mammal infected with hiv virus, and triple mutant protein" - Google Patents
"compound, composition, method for treating a mammal infected with hiv virus, and triple mutant protein"Info
- Publication number
- BR112018015629A2 BR112018015629A2 BR112018015629-9A BR112018015629A BR112018015629A2 BR 112018015629 A2 BR112018015629 A2 BR 112018015629A2 BR 112018015629 A BR112018015629 A BR 112018015629A BR 112018015629 A2 BR112018015629 A2 BR 112018015629A2
- Authority
- BR
- Brazil
- Prior art keywords
- treating
- compound
- composition
- mutant protein
- hiv virus
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J53/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by condensation with a carbocyclic rings or by formation of an additional ring by means of a direct link between two ring carbon atoms, including carboxyclic rings fused to the cyclopenta(a)hydrophenanthrene skeleton are included in this class
- C07J53/002—Carbocyclic rings fused
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07J—STEROIDS
- C07J63/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton has been modified by expansion of only one ring by one or two atoms
- C07J63/008—Expansion of ring D by one atom, e.g. D homo steroids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/503—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses
- C12N9/506—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from viruses derived from RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2603/00—Systems containing at least three condensed rings
- C07C2603/02—Ortho- or ortho- and peri-condensed systems
- C07C2603/52—Ortho- or ortho- and peri-condensed systems containing five condensed rings
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
- C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- AIDS & HIV (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Epidemiology (AREA)
- Steroid Compounds (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Abstract
compostos tendo propriedades de fármacos e bioativas, suas composições farmacêuticas e métodos de uso são expostos. em particular, derivados de ácido betulínico que possuem atividade antiviral única são providos como inibidores de maturação do hiv, como representado por compostos de fórmula (i). esses compostos são úteis para o tratamento de hiv e aids.compounds having drug and bioactive properties, their pharmaceutical compositions and methods of use are exposed. in particular, betulinic acid derivatives having unique antiviral activity are provided as inhibitors of hiv maturation as represented by compounds of formula (i). These compounds are useful for the treatment of HIV and AIDS.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662291298P | 2016-02-04 | 2016-02-04 | |
| US62/291,298 | 2016-02-04 | ||
| US62/291298 | 2016-02-04 | ||
| PCT/IB2017/050568 WO2017134596A1 (en) | 2016-02-04 | 2017-02-02 | C-3 and c-17 modified triterpenoids as hiv-1 inhibitors |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| BR112018015629A2 true BR112018015629A2 (en) | 2018-12-26 |
| BR112018015629B1 BR112018015629B1 (en) | 2023-10-24 |
Family
ID=57995251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018015629-9A BR112018015629B1 (en) | 2016-02-04 | 2017-02-02 | COMPOUNDS DERIVED FROM BETULINIC ACID AND COMPOSITION |
Country Status (38)
| Country | Link |
|---|---|
| US (4) | US10421774B2 (en) |
| EP (2) | EP3831839B1 (en) |
| JP (1) | JP6735837B2 (en) |
| KR (1) | KR20180105229A (en) |
| CN (1) | CN109153700B (en) |
| AR (1) | AR107512A1 (en) |
| AU (1) | AU2017215529B2 (en) |
| BR (1) | BR112018015629B1 (en) |
| CA (1) | CA3013417C (en) |
| CL (1) | CL2018002084A1 (en) |
| CO (1) | CO2018008157A2 (en) |
| CR (1) | CR20180387A (en) |
| CY (1) | CY1124353T1 (en) |
| DK (1) | DK3411381T3 (en) |
| DO (1) | DOP2018000174A (en) |
| EA (1) | EA036211B1 (en) |
| ES (2) | ES2957767T3 (en) |
| HK (1) | HK1256866A1 (en) |
| HR (1) | HRP20210502T1 (en) |
| HU (1) | HUE054337T2 (en) |
| IL (1) | IL260741B (en) |
| JO (1) | JOP20170029B1 (en) |
| LT (1) | LT3411381T (en) |
| MA (2) | MA43960B1 (en) |
| MD (1) | MD3411381T2 (en) |
| MX (1) | MX2018009514A (en) |
| PE (1) | PE20181355A1 (en) |
| PL (1) | PL3411381T3 (en) |
| PT (1) | PT3411381T (en) |
| RS (1) | RS61746B1 (en) |
| RU (1) | RU2716502C2 (en) |
| SG (1) | SG11201806388XA (en) |
| SI (1) | SI3411381T1 (en) |
| TW (1) | TWI719126B (en) |
| UA (1) | UA123867C2 (en) |
| UY (1) | UY37109A (en) |
| WO (1) | WO2017134596A1 (en) |
| ZA (1) | ZA201805044B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR107512A1 (en) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | TRITERPENOIDS MODIFIED IN C-3 AND C-17 AS HIV-1 INHIBITORS |
| EP4321164A3 (en) | 2018-04-24 | 2024-04-17 | ViiV Healthcare UK (No.5) Limited | Compounds with hiv maturation inhibitory activity |
| TW202135815A (en) | 2019-12-09 | 2021-10-01 | 美商 Ｖｉｉｖ 醫療保健公司 | Pharmacuetical compositions |
| WO2024089216A1 (en) | 2022-10-27 | 2024-05-02 | Syngenta Crop Protection Ag | Novel sulfur-containing heteroaryl carboxamide compounds |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5413999A (en) | 1991-11-08 | 1995-05-09 | Merck & Co., Inc. | HIV protease inhibitors useful for the treatment of AIDS |
| US5679828A (en) | 1995-06-05 | 1997-10-21 | Biotech Research Labs, Inc. | Betulinic acid and dihydrobetulinic acid derivatives and uses therefor |
| US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
| US7365221B2 (en) | 2002-09-26 | 2008-04-29 | Panacos Pharmaceuticals, Inc. | Monoacylated betulin and dihydrobetulin derivatives, preparation thereof and use thereof |
| GB0301227D0 (en) | 2003-01-20 | 2003-02-19 | Keen Group Ltd | Seating apparatus |
| US7745625B2 (en) | 2004-03-15 | 2010-06-29 | Bristol-Myers Squibb Company | Prodrugs of piperazine and substituted piperidine antiviral agents |
| BRPI0508854A (en) | 2004-03-17 | 2007-08-28 | Panacos Pharmaceuticals Inc | pharmaceutical salts of 3-o- (3 ', 3'-dimethylsuccinyl) betulinic acid |
| TW200628161A (en) | 2004-11-12 | 2006-08-16 | Panacos Pharmaceuticals Inc | Novel betulin derivatives, preparation thereof and use thereof |
| WO2008115281A2 (en) | 2006-10-16 | 2008-09-25 | Myriad Genetics, Inc. | Compounds for treating viral infections |
| CA2714049A1 (en) | 2008-02-14 | 2009-08-20 | Virochem Pharma Inc. | Novel 17.beta. lupane derivatives |
| US9067966B2 (en) | 2009-07-14 | 2015-06-30 | Hetero Research Foundation, Hetero Drugs Ltd. | Lupeol-type triterpene derivatives as antivirals |
| FR2956034B1 (en) | 2010-02-09 | 2012-02-10 | Thales Sa | TRAINING DEVICE FOR RUGBY PLAYERS |
| BR112012030818A2 (en) | 2010-06-04 | 2019-09-24 | Bristol-Myers Squibb Company | "modified c-3 betulinic acid derivatives as inhibitors of hiv maturation" |
| EP2576586B1 (en) | 2010-06-04 | 2015-08-12 | Bristol-Myers Squibb Company | C-28 amides of modified c-3 betulinic acid derivatives as hiv maturation inhibitors |
| DE102010017786A1 (en) | 2010-07-07 | 2012-01-12 | Continental Reifen Deutschland Gmbh | Elastomer product containing a linear textile structure for reinforcement |
| EA022470B1 (en) * | 2011-01-31 | 2016-01-29 | Бристол-Маерс Сквибб Компани | C-17 and c-3 modified triterpenoids with hiv maturation inhibitory activity |
| CN103339141B (en) | 2011-01-31 | 2016-08-24 | 百时美施贵宝公司 | C-28 amine as the betulinic acid derivative that the C-3 of HIV maturation inhibitor modifies |
| CA2859032A1 (en) * | 2011-12-14 | 2013-06-20 | Glaxosmithkline Llc | Propenoate derivatives of betulin |
| US8906889B2 (en) * | 2012-02-15 | 2014-12-09 | Bristol-Myers Squibb Company | C-3 cycloalkenyl triterpenoids with HIV maturation inhibitory activity |
| US8889854B2 (en) * | 2012-05-07 | 2014-11-18 | Bristol-Myers Squibb Company | C-17 bicyclic amines of triterpenoids with HIV maturation inhibitory activity |
| US9908887B2 (en) | 2012-12-21 | 2018-03-06 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| US9378035B2 (en) | 2012-12-28 | 2016-06-28 | Commvault Systems, Inc. | Systems and methods for repurposing virtual machines |
| CN105121454A (en) * | 2013-02-06 | 2015-12-02 | 百时美施贵宝公司 | C-19 modified triterpenoids with HIV maturation inhibitory activity |
| SG11201506445PA (en) | 2013-02-25 | 2015-09-29 | Bristol Myers Squibb Co | C-3 alkyl and alkenyl modified betulinic acid derivatives useful in the treatment of hiv |
| CN104877015B (en) * | 2014-02-28 | 2019-02-01 | 中国人民解放军军事医学科学院毒物药物研究所 | A kind of triterpene-polypeptide conjugate, its pharmaceutical composition and purposes |
| EP3129392B1 (en) * | 2014-04-11 | 2020-08-05 | VIIV Healthcare UK(No.4) Limited | Triterpenoids with hiv maturation inhibitory activity, substituted in position 3 by a non-aromatic ring carrying a haloalkyl substituent |
| MA40886B1 (en) | 2015-02-09 | 2020-03-31 | Hetero Research Foundation | Novel c-3 triterpenone with c-28 reverse amide derivatives as hiv inhibitors |
| AR107512A1 (en) * | 2016-02-04 | 2018-05-09 | VIIV HEALTHCARE UK Nº 5 LTD | TRITERPENOIDS MODIFIED IN C-3 AND C-17 AS HIV-1 INHIBITORS |
| ES2907373T3 (en) | 2016-02-04 | 2022-04-25 | Takeda Pharmaceuticals Co | Substituted piperidine compound and use thereof |
-
2017
- 2017-02-01 AR ARP170100255A patent/AR107512A1/en unknown
- 2017-02-02 US US16/071,925 patent/US10421774B2/en active Active
- 2017-02-02 PL PL17704093T patent/PL3411381T3/en unknown
- 2017-02-02 EP EP21152161.2A patent/EP3831839B1/en active Active
- 2017-02-02 RS RS20210450A patent/RS61746B1/en unknown
- 2017-02-02 TW TW106103410A patent/TWI719126B/en active
- 2017-02-02 KR KR1020187025343A patent/KR20180105229A/en not_active Application Discontinuation
- 2017-02-02 UY UY0001037109A patent/UY37109A/en not_active Application Discontinuation
- 2017-02-02 MD MDE20181181T patent/MD3411381T2/en unknown
- 2017-02-02 SI SI201730647T patent/SI3411381T1/en unknown
- 2017-02-02 SG SG11201806388XA patent/SG11201806388XA/en unknown
- 2017-02-02 MX MX2018009514A patent/MX2018009514A/en active IP Right Grant
- 2017-02-02 EP EP17704093.8A patent/EP3411381B1/en active Active
- 2017-02-02 UA UAA201808249A patent/UA123867C2/en unknown
- 2017-02-02 AU AU2017215529A patent/AU2017215529B2/en active Active
- 2017-02-02 RU RU2018130181A patent/RU2716502C2/en active
- 2017-02-02 JO JOP/2017/0029A patent/JOP20170029B1/en active
- 2017-02-02 WO PCT/IB2017/050568 patent/WO2017134596A1/en active Application Filing
- 2017-02-02 CR CR20180387A patent/CR20180387A/en unknown
- 2017-02-02 LT LTEP17704093.8T patent/LT3411381T/en unknown
- 2017-02-02 CN CN201780018790.8A patent/CN109153700B/en active Active
- 2017-02-02 MA MA43960A patent/MA43960B1/en unknown
- 2017-02-02 EA EA201891649A patent/EA036211B1/en unknown
- 2017-02-02 HU HUE17704093A patent/HUE054337T2/en unknown
- 2017-02-02 DK DK17704093.8T patent/DK3411381T3/en active
- 2017-02-02 MA MA053358A patent/MA53358A/en unknown
- 2017-02-02 ES ES21152161T patent/ES2957767T3/en active Active
- 2017-02-02 ES ES17704093T patent/ES2862325T3/en active Active
- 2017-02-02 PE PE2018001378A patent/PE20181355A1/en unknown
- 2017-02-02 CA CA3013417A patent/CA3013417C/en active Active
- 2017-02-02 PT PT177040938T patent/PT3411381T/en unknown
- 2017-02-02 JP JP2018540806A patent/JP6735837B2/en active Active
- 2017-02-02 BR BR112018015629-9A patent/BR112018015629B1/en active IP Right Grant
-
2018
- 2018-07-23 IL IL260741A patent/IL260741B/en active IP Right Grant
- 2018-07-26 ZA ZA2018/05044A patent/ZA201805044B/en unknown
- 2018-07-30 DO DO2018000174A patent/DOP2018000174A/en unknown
- 2018-07-31 CO CONC2018/0008157A patent/CO2018008157A2/en unknown
- 2018-08-02 CL CL2018002084A patent/CL2018002084A1/en unknown
- 2018-12-12 HK HK18115964.0A patent/HK1256866A1/en unknown
-
2019
- 2019-08-07 US US16/534,208 patent/US11084845B2/en active Active
-
2021
- 2021-03-29 HR HRP20210502TT patent/HRP20210502T1/en unknown
- 2021-04-08 CY CY20211100303T patent/CY1124353T1/en unknown
- 2021-06-09 US US17/342,941 patent/US20210323997A1/en not_active Abandoned
-
2022
- 2022-12-16 US US18/083,037 patent/US20230295220A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EA201992082A1 (en) | HEPATITIS B VIRUS SURFACE ANTIGEN INHIBITOR | |
| BR112018075465A2 (en) | hepatitis b antiviral agents | |
| UY37997A (en) | ANTIVIRAL AGENTS AGAINST HEPATITIS B | |
| UY37998A (en) | ANTIVIRAL AGENTS AGAINST HEPATITIS B | |
| MX2018009633A (en) | Inhibitor of indoleamine-2,3-dioxygenase (ido). | |
| ECSP14006132A (en) | BENZOTHIAZOLE-6-IL ACETIC ACID DERIVATIVES AND THEIR USE TO TREAT HIV INFECTION | |
| BR112022004424A2 (en) | Antiviral prodrugs and their formulations | |
| BR112017022544A2 (en) | "compound, composition, and method for treating hiv infection". | |
| BR112015028879A8 (en) | heterocyclic derivative compounds, pharmaceutical composition comprising said compounds and uses thereof | |
| CU20150096A7 (en) | AMIDA COMPOUNDS AND PHARMACEUTICAL COMPOSITION FOR HIV TREATMENT | |
| UY37645A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| CO2018008421A2 (en) | Indoline derivatives substituted as inhibitors of dengue viral replication | |
| EA201791776A1 (en) | SUBSTITUTED CYCLOPHANES FOR USE WHEN TREATING HCV INFECTION | |
| UY37646A (en) | INDOLINA DERIVATIVES REPLACED AS INHIBITORS OF THE DENGUE VIRIC REPLICATION | |
| CL2011002878A1 (en) | Compounds derived from thieno [2,3-b] pyridines, inhibitors of hiv virus replication; preparation procedure; pharmaceutical composition; and use of the compound to prevent or treat an HIV infection. | |
| BR112015013695A2 (en) | pharmaceutical composition and methods for treating and preventing an HIV infection | |
| UY38383A (en) | HETEROCYCLES FUNCTIONALIZED AS ANTIVIRAL AGENTS | |
| BR112018015629A2 (en) | "compound, composition, method for treating a mammal infected with hiv virus, and triple mutant protein" | |
| BR112017000246A2 (en) | compound, pharmaceutically acceptable salt of a compound, pharmaceutical composition, and use of a compound or salt | |
| DOP2018000035A (en) | ACID DERIVATIVES 5- (N-BENCIL-TETRAHYDROISOQUINOLIN-6-IL) -PIRIDIN-3-IL ACETIC AS INHIBITORS OF HUMAN IMMUNODEFICIENCY VIRUS REPLICATION | |
| BR112022006018A2 (en) | HETEROARYL-BIPHENYL AMIDES FOR THE TREATMENT OF PD-L1-RELATED DISEASES | |
| BR112015023356A2 (en) | pyrrol [2,3-b] pyridine cdk9 kinase inhibitors | |
| PH12019502376A1 (en) | Pyrrolopyrimidine derivatives useful as inhibitors of influenza virus replication | |
| BR112015026840A2 (en) | compound, pharmaceutically acceptable salt, pharmaceutical composition, use of a compound, and method for preventing or treating hyperphosphatemia | |
| BR112015005347A2 (en) | compound, pharmaceutical composition, and method for treatment or prophylaxis of HIV infection or for treatment, prophylaxis, or delay in the onset of AIDS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B15K | Others concerning applications: alteration of classification |
Free format text: AS CLASSIFICACOES ANTERIORES ERAM: C07J 63/00 , C12N 9/50 , A61K 31/575 , A61K 31/56 , A61K 31/58 , A61P 31/18 Ipc: A61K 31/575 (2006.01), C12N 9/50 (2006.01), C07J 6 |
|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B09A | Decision: intention to grant [chapter 9.1 patent gazette] | ||
| B16A | Patent or certificate of addition of invention granted [chapter 16.1 patent gazette] |
Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 02/02/2017, OBSERVADAS AS CONDICOES LEGAIS |